Kevin Feeley sold $202k of WGS
CHIEF FINANCIAL OFFICER at GeneDx Holdings Corp.. 1,266 shares at an average of $159.28, traded Dec 9, 2025, filed Dec 11, 2025.
Score components
- +22RoleCFO
- +12Trade size$202k at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001944119-25-000020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2025 | MOption exercise Class A Common Stock | +2,462 | $0.00 | $0 | 6,655 | Dec 11, 2025 |
| Dec 9, 2025 | SOpen-market sale Class A Common Stock | -1,266 | $159.28 | $202k | 5,389 | Dec 11, 2025 |
| Dec 9, 2025 | MOption exercise Restricted Stock Unitderivative | -2,462 | $0.00 | $0 | 9,849 | Dec 11, 2025 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 44Moderate | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $555k 3,855 shares | -31% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.6M 10,857 shares | -43% | |
| 47Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $580k 3,639 shares | -36% | |
| 29Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $61k 377 shares | -8% | |
| 68Notable | GeneDx Holdings Corp. | Joshua Ruch director | $6.1M 38,000 shares | -256% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.